Dyne Therapeutics, Inc. Net Income
Dyne Therapeutics, Inc. (DYN) reported Net Income of -$178.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-07-29
- Dyne Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$178.56M.
- Dyne Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$120.85M.
- Dyne Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $334.26M, a 46.68% increase year-over-year.
- Dyne Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$108.04M.
- Dyne Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2021 was -$149.29M.
- Dyne Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2020 was -$59.44M.
- Dyne Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2019 was -$14.86M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$178.56M 10-Q · filed 2026-07-29 | -$299.41M 10-Q · filed 2026-07-29 | $34.85M derived: sum of 3 quarters · filed 2026-07-29 | -$73.19M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2026-03-31 | -$120.85M 10-Q · filed 2026-07-29 | $213.40M derived: sum of 2 quarters · filed 2026-07-29 | $105.36M derived: sum of 3 quarters · filed 2026-07-29 | -$5.49M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-12-31 | $334.26M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-23 | $226.22M derived: sum of 2 quarters · filed 2026-04-23 | $115.36M derived: sum of 3 quarters · filed 2026-07-29 | -$446.20 DEF 14A · filed 2026-04-23 | -$446.21M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$108.04M 10-Q · filed 2025-11-05 | -$218.90M derived: sum of 2 quarters · filed 2026-07-29 | -$334.26M 10-Q · filed 2025-11-05 | -$106.38M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-06-30 | -$110.86M 10-Q · filed 2026-07-29 | -$226.22M 10-Q · filed 2026-07-29 | $1.66M derived: sum of 3 quarters · filed 2026-07-29 | -$95.47M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-03-31 | -$115.36M 10-Q · filed 2026-07-29 | $112.51M derived: sum of 2 quarters · filed 2026-07-29 | $15.39M derived: sum of 3 quarters · filed 2026-07-29 | -$49.71M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2024-12-31 | $227.88M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-23 | $130.75M derived: sum of 2 quarters · filed 2026-04-23 | $65.65M derived: sum of 3 quarters · filed 2026-04-23 | -$317.40 DEF 14A · filed 2026-04-23 | -$317.42M 10-K · filed 2025-02-27 |
| 2024-09-30 | -$97.13M 10-Q · filed 2025-11-05 | -$162.23M derived: sum of 2 quarters · filed 2025-11-05 | -$227.88M 10-Q · filed 2025-11-05 | -$58.58M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2024-06-30 | -$65.10M 10-Q · filed 2025-11-05 | -$130.75M 10-Q · filed 2025-07-28 | $38.55M derived: sum of 3 quarters · filed 2026-04-23 | -$21.66M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2024-03-31 | -$65.65M 10-Q · filed 2025-11-05 | $103.65M derived: sum of 2 quarters · filed 2026-04-23 | $43.44M derived: sum of 3 quarters · filed 2026-04-23 | -$21.46M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2023-12-31 | $169.30M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-23 | $109.09M derived: sum of 2 quarters · filed 2026-04-23 | $44.19M derived: sum of 3 quarters · filed 2026-04-23 | -$235.90 DEF 14A · filed 2026-04-23 | -$235.94M 10-K · filed 2024-03-05 |
| 2023-09-30 | -$60.21M 10-Q · filed 2024-11-12 | -$125.11M derived: sum of 2 quarters · filed 2024-11-12 | -$169.30M 10-Q · filed 2024-11-12 | -$40.03M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2023-06-30 | -$64.90M 10-Q · filed 2024-11-12 | -$109.09M 10-Q · filed 2024-08-12 | $20.18M derived: sum of 3 quarters · filed 2026-04-23 | -$21.20M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2023-03-31 | -$44.19M 10-Q · filed 2024-11-12 | $85.08M derived: sum of 2 quarters · filed 2026-04-23 | $43.70M derived: sum of 3 quarters · filed 2026-04-23 | -$8.60M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2022-12-31 | $129.27M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-23 | $87.89M derived: sum of 2 quarters · filed 2026-04-23 | $35.58M derived: sum of 3 quarters · filed 2026-04-23 | -$168.10 DEF 14A · filed 2026-04-23 | -$168.10M 10-K · filed 2023-03-02 |
| 2022-09-30 | -$41.38M 10-Q · filed 2023-10-30 | -$93.69M derived: sum of 2 quarters · filed 2023-10-30 | -$129.27M 10-Q · filed 2023-10-30 | -$181.06M derived: sum of 4 quarters · filed 2023-10-30 | |
| 2022-06-30 | -$52.30M 10-Q · filed 2023-10-30 | -$87.89M 10-Q · filed 2023-08-03 | -$139.67M derived: sum of 3 quarters · filed 2023-10-30 | -$182.25M derived: sum of 4 quarters · filed 2023-10-30 | |
| 2022-03-31 | -$35.58M 10-Q · filed 2023-10-30 | -$87.37M derived: sum of 2 quarters · filed 2023-10-30 | -$129.95M derived: sum of 3 quarters · filed 2023-10-30 | -$159.91M derived: sum of 4 quarters · filed 2023-10-30 | |
| 2021-12-31 | -$51.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$94.37M derived: sum of 2 quarters · filed 2023-03-02 | -$124.32M derived: sum of 3 quarters · filed 2023-03-02 | -$149.29M 10-K · filed 2023-03-02 | |
| 2021-09-30 | -$42.58M 10-Q · filed 2022-11-03 | -$72.54M derived: sum of 2 quarters · filed 2022-11-03 | -$97.50M 10-Q · filed 2022-11-03 | -$126.15M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | -$29.95M 10-Q · filed 2022-11-03 | -$54.92M 10-Q · filed 2022-08-04 | -$83.57M derived: sum of 3 quarters · filed 2022-11-03 | -$97.49M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-03-31 | -$24.97M 10-Q · filed 2022-11-03 | -$53.62M derived: sum of 2 quarters · filed 2022-11-03 | -$67.54M derived: sum of 3 quarters · filed 2022-11-03 | -$76.52M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2020-12-31 | -$28.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$42.57M derived: sum of 2 quarters · filed 2022-03-10 | -$51.55M derived: sum of 3 quarters · filed 2022-03-10 | -$59.44M 10-K · filed 2022-03-10 | |
| 2020-09-30 | -$13.92M 10-Q · filed 2021-11-04 | -$22.90M derived: sum of 2 quarters · filed 2021-11-04 | -$30.79M 10-Q · filed 2021-11-04 | -$36.19M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | -$8.98M 10-Q · filed 2021-11-04 | -$16.87M 10-Q · filed 2021-08-05 | -$22.27M derived: sum of 3 quarters · filed 2021-11-04 | -$28.14M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-03-31 | -$7.89M 10-Q · filed 2021-11-04 | -$13.29M derived: sum of 2 quarters · filed 2021-11-04 | -$19.16M derived: sum of 3 quarters · filed 2021-11-04 | -$20.66M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2019-12-31 | -$5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$11.27M derived: sum of 2 quarters · filed 2021-03-04 | -$12.77M derived: sum of 3 quarters · filed 2021-03-04 | -$14.86M 10-K · filed 2021-03-04 | -$14.90M 10-Q · filed 2020-11-05 |
| 2019-09-30 | -$5.87M 10-Q · filed 2020-11-05 | -$7.37M derived: sum of 2 quarters · filed 2020-11-05 | -$9.46M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | -$1.50M 10-Q · filed 2020-11-05 | -$3.58M derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-31 | -$2.09M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |